Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline
Covered in this story
Call it yourself
No calls on $PFS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Provident Financial Services Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.